This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Seagen Inc.
Seagen Inc., a leading biotechnology company headquartered in the United States, is at the forefront of developing innovative cancer therapies. Founded in 1998, Seagen has made significant strides in the oncology sector, particularly in the development of antibody-drug conjugates (ADCs) that target specific cancer cells while minimising damage to healthy tissue. With a strong presence in major operational regions including North America and Europe, Seagen's core products, such as ADCETRIS and PADCEV, are recognised for their unique mechanisms of action and efficacy in treating various types of cancer. The company has established itself as a key player in the biopharmaceutical industry, achieving notable milestones such as FDA approvals and partnerships that enhance its market position. Seagen continues to drive innovation in cancer treatment, aiming to improve patient outcomes worldwide.
DitchCarbon Score
How does Seagen Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Seagen Inc.'s score of 82 is higher than 90% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Seagen Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Pfizer Inc., and as such, it inherits emissions data and climate commitments from its parent organisation. Seagen's climate initiatives are aligned with those of Pfizer Inc., which has set various reduction targets through the Science Based Targets initiative (SBTi) and participates in the Carbon Disclosure Project (CDP). These initiatives aim to enhance transparency and accountability in emissions reporting and reduction efforts. While specific reduction targets for Seagen Inc. are not detailed, the company's commitment to sustainability is reflected in its alignment with Pfizer's broader climate strategies, including participation in initiatives like RE100 and the Race to Zero campaign. As of now, Seagen Inc. has not publicly disclosed its own emissions figures or specific reduction commitments, but it is expected to follow the sustainability framework established by Pfizer Inc. in its ongoing efforts to address climate change.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | - | - | - | - | - | - | - | - | 000,000,000 | 000,000,000 | - | - | - |
| Scope 2 | - | - | - | - | - | - | - | - | 000,000,000 | 000,000,000 | - | - | - |
| Scope 3 | - | - | - | - | - | - | - | 000,000,000 | 0,000,000,000 | 0,000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Seagen Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
